Research summary ·
Synaptic vesicle glycoprotein 2A PET imaging in parkinsonian α-synucleinopathies: a systematic review.
Written based on 1 research study on PubMed, searched on 3 Nov 2026.
What was studied
This review looked at brain PET scans that show synapses. The tracer binds SV2A. SV2A is a protein in nerve endings. The scans were used in Parkinson's disease and dementia with Lewy bodies. They were also used in MSA. MSA is multiple system atrophy. The review looked at scan patterns and links to symptoms. It also looked at change over time and at how scans are read.
What they found
In Parkinson's disease, SV2A binding was most often low in the substantia nigra. Other brain areas were reported in some groups. In dementia, changes seemed broader and more cortical. Cortical binding was linked to thinking scores. In MSA, one study suggested a distinct cerebellar pattern.
What it means for patients
The authors call SV2A PET a research biomarker for these diseases. They say it may help sort patients by type, especially in MSA.
Why it is not certain yet
The field is limited by small groups and mixed methods. Ways of measuring binding varied. Evidence over time is limited. Some groups may overlap. The authors say multicentre validation and shared protocols are needed before clinical use. The abstract gives no number of patients.
Source
Synaptic vesicle glycoprotein 2A PET imaging in parkinsonian α-synucleinopathies: a systematic review.
PubMed · PMID 42704496We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Lewy body dementia publications